PMID- 25435128
OWN - NLM
STAT- MEDLINE
DCOM- 20150918
LR  - 20181202
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 15
IP  - 4
DP  - 2015 Apr
TI  - Analysis of adverse events following the treatment of autologous cytokine-induced 
      killer cells for adoptive immunotherapy in malignant tumour sufferers.
PG  - 481-93
LID - 10.1517/14712598.2015.988134 [doi]
AB  - BACKGROUND: Adoptive immune cell transfer such as cytokine-induced killer (CIK) 
      cells has become an important adjuvant approach in patients with tumours. 
      OBJECTIVES: The aim of this study was to analyse the adverse events (AEs) that 
      occur during the transfusion of autologous CIK cells and to identify the risk 
      factors associated with these AEs. METHODS: Cell infusion-associated AEs were 
      evaluated according to National Cancer Institute Common Terminology Criteria. 
      Analysis was performed from a single-centre data on 893 malignant tumour patients 
      who received a total of 4088 transfusions from March 2008 to October 2013. 
      RESULTS: A total of 215/4088 (5.26%) transfusion cases from 893 patients 
      presented with AEs (Grade 1 - 4); 204/215 (94.88%) were Grade 1 - 2, and 156/215 
      (72.56%) occurred within 24 h. The most common AEs were fever (0.88%), chills 
      (0.56%) and fatigue (0.49%). The rare but severe AEs included anaphylactoid 
      purpura, tumour lysis syndrome, anaphylactic shock, arthralgia. No 
      transfusion-associated death was noticed. The mainly relative risk factors for 
      AEs included transfer cycles and clinical stages. CONCLUSION: This study is a 
      large-sample AEs research, to our knowledge, relative to immune cell transfusion 
      from a single centre data analysis, revealing that autologous CIK cell therapy 
      represents a fairly safe and well-tolerated treatment modality for malignant 
      tumour patients, even rare severe, but not lethal AEs were observed in few 
      patients.
FAU - Zhang, Yajing
AU  - Zhang Y
AD  - College of Life Science, Chinese PLA General Hospital, Biotherapeutic Department 
      , 28 Fuxing Road, HaiDian District, Beijing 100853 , China hanwdrsw69@yahoo.com.
FAU - Xia, Lei
AU  - Xia L
FAU - Zhang, Yan
AU  - Zhang Y
FAU - Wang, Yao
AU  - Wang Y
FAU - Lu, Xuechun
AU  - Lu X
FAU - Shi, Fengxia
AU  - Shi F
FAU - Liu, Yang
AU  - Liu Y
FAU - Chen, Meixia
AU  - Chen M
FAU - Feng, Kaixhao
AU  - Feng K
FAU - Zhang, Wenying
AU  - Zhang W
FAU - Fu, Xiaobing
AU  - Fu X
FAU - Han, Weidong
AU  - Han W
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141201
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Blood Transfusion, Autologous/adverse effects
MH  - Cytokine-Induced Killer Cells/immunology/*transplantation
MH  - Female
MH  - Humans
MH  - *Immunotherapy, Adoptive/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*diagnosis/immunology/*therapy
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adverse events
OT  - cytokine-induced killer cells
OT  - risk factor
OT  - single-centre study
EDAT- 2014/12/02 06:00
MHDA- 2015/09/19 06:00
CRDT- 2014/12/02 06:00
PHST- 2014/12/02 06:00 [entrez]
PHST- 2014/12/02 06:00 [pubmed]
PHST- 2015/09/19 06:00 [medline]
AID - 10.1517/14712598.2015.988134 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2015 Apr;15(4):481-93. doi: 10.1517/14712598.2015.988134. 
      Epub 2014 Dec 1.